Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bitdeer Technologies Group (BTDR) vs Merck & Co., Inc. (MRK) Price & Performance

Bitdeer Technologies GroupTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Bitdeer Technologies Group vs Merck & Co., Inc. — how do they compare? Bitdeer Technologies Group trades at $9.09 (market cap $2.36B), while Merck & Co., Inc. trades at $129.74 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 136.3× Bitdeer Technologies Group's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Bitdeer Technologies Group pays none. Which is the better fit depends on your goals.

BTDRMRK
Market Cap
$2.36B$321.77B
Sector
TechnologyHealth
52-Week High
$25.90$131.84
52-Week Low
$7.28$77.60
Enterprise Value
$3.85B$368.53B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bitdeer Technologies Group

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.

The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bitdeer Technologies Group

Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.

Read more on BTDR

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK